EUVIMEDEUVIMED entdecken
Open Access

Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP

Jennifer K Litton iD, Meredith M Regan iD, Lajos Pusztai iD, Hope S Rugo iD, Sara M Tolaney iD, Elizabeth Garrett-Mayer iD, Laleh Amiri-Kordestani iD, Reva K Basho iD, Ana F Best iD, Jean-Francois Boileau iD, Carsten Denkert iD, Jared C Foster iD und 15 weitere

Journal of Clinical Oncology · 20.09.2023 · 41 (27) · 4433-4442

DOI: 10.1200/jco.23.00435 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.09.2023. Verfasst von Jennifer K Litton und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 123-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The Standardized Definitions for Efficacy End Points (STEEP) criteria, established in 2007 and updated in 2021 (STEEP 2.0), provide standardized definitions of adjuvant breast cancer (BC) end points. STEEP 2.0 identified a need to separately address end points for neoadjuvant clinical trials. The multidisciplinary NeoSTEEP working group of experts was convened to critically evaluate and align neoadjuvant BC trial end points. METHODS The NeoSTEEP working group concentrated on neoadjuvant systemic therapy end points in clinical trials with efficacy outcomes—both pathologic and time-to-event survival end points—particularly for registrational intent. Special considerations for subtypes and therapeutic approaches, imaging, nodal staging at surgery, bilateral and multifocal diseases, correlative tissue collection, and US Food and Drug Administration regulatory considerations were contemplated. RESULTS The working group recommends a preferred definition of pathologic complete response (pCR) as the absence of residual invasive cancer in the complete resected breast specimen and all sampled regional lymph nodes (ypT0/Tis ypN0 per AJCC staging). Residual cancer burden should be a secondary end point to facilitate future assessment of its utility. Alternative end points are needed for hormone receptor–positive disease. Time-to-event survival end point definitions should pay particular attention to the measurement starting point. Trials should include end points originating at random assignment (event-free survival and overall survival) to capture presurgery progression and deaths as events. Secondary end points adapted from STEEP 2.0, which are defined from starting at curative-intent surgery, may also be appropriate. Specification and standardization of biopsy protocols, imaging, and pathologic nodal evaluation are also crucial. CONCLUSION End points in addition to pCR should be selected on the basis of clinical and biologic aspects of the tumor and the therapeutic agent investigated. Consistent prespecified definitions and interventions are paramount for clinically meaningful trial results and cross-trial comparison.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsHumansFemaleNeoadjuvant TherapyResearch DesignProgression-Free Survival

Autor:innen und Institutionen

  • Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Division of Biostatistics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Breast Medical Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT.
  • University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA.
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • American Society of Clinical Oncology, Alexandria, VA.

ORCID-Profile: Jennifer K Litton, Meredith M Regan, Lajos Pusztai, Hope S Rugo, Sara M Tolaney, Elizabeth Garrett-Mayer, Laleh Amiri-Kordestani, Reva K Basho, Ana F Best, Jean-Francois Boileau, Carsten Denkert, Jared C Foster, Nadia Harbeck, Heather A Jacene, Ciara C O'Sullivan, Tatiana M Prowell, Gulisa Turashvili, Wendy A Woodward

Förderung

  • NCATS NIH HHS

Zitieren

APA

Litton, J. K., Regan, M. M., Pusztai, L., Rugo, H. S., Tolaney, S. M., Garrett-Mayer, E., Amiri-Kordestani, L., Basho, R. K., Best, A. F., Boileau, J. F., Denkert, C., Foster, J. C., Harbeck, N., Jacene, H. A., King, T. A., Mason, G., O'Sullivan, C. C., Prowell, T. M., Richardson, A. L., …, & Korde, L. A. (2023). Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP. Journal of Clinical Oncology, 41(27), 4433-4442. https://doi.org/10.1200/jco.23.00435

Vancouver

Litton JK, Regan MM, Pusztai L, Rugo HS, Tolaney SM, Garrett-Mayer E, et al. Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP. Journal of Clinical Oncology. 2023;41(27):4433-4442. doi:10.1200/jco.23.00435

BibTeX
@article{Litton2023,
  author = {Litton, Jennifer K and Regan, Meredith M and Pusztai, Lajos and Rugo, Hope S and Tolaney, Sara M and Garrett-Mayer, Elizabeth and Amiri-Kordestani, Laleh and Basho, Reva K and Best, Ana F and Boileau, Jean-Francois and Denkert, Carsten and Foster, Jared C and Harbeck, Nadia and Jacene, Heather A and King, Tari A and Mason, Ginny and O'Sullivan, Ciara C and Prowell, Tatiana M and Richardson, Andrea L and Sepulveda, Karla A and Smith, Mary Lou and Tjoe, Judy A and Turashvili, Gulisa and Woodward, Wendy A and Butler, Lynn Pearson and Schwartz, Elena I and Korde, Larissa A},
  title = {Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP},
  journal = {Journal of Clinical Oncology},
  year = {2023},
  volume = {41},
  number = {27},
  pages = {4433--4442},
  doi = {10.1200/jco.23.00435}
}
Kostenlos starten →